Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today the completion of its previously announced underwritten public offering of
View HTML
Toggle Summary Conatus Announces Pricing of Public Offering of Common Stock
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it has priced an underwritten public offering of 5,200,000 shares of its
View HTML
Toggle Summary Conatus Announces Proposed Public Offering of Common Stock
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it intends to offer and sell shares of its common stock in an underwritten
View HTML
Toggle Summary Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2017, and provided updates on its development programs. Conatus is developing emricasan, its first-in-class, orally active pan-caspase
View HTML
Toggle Summary Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Novartis has exercised its option to an exclusive license for the global development and commercialization of emricasan, the company's first-in-class, orally-active pan-caspase inhibitor,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the market close on Thursday, May 4, 2017. Conatus will host a conference call and audio webcast at 4:30
View HTML
Toggle Summary Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The International Liver Congress™ 2017, the Annual Meeting of the European Association for the
View HTML
Toggle Summary Conatus to Present at Upcoming Investor Conferences
SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company's scheduled presentations at two upcoming investor conferences in New York: H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3.
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided updates on its clinical development programs. Conatus is developing emricasan, its first-in-class,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, after the market close on Wednesday, March 15, 2017.
View HTML